Additionally, it has been revealed that treatment using an anti-KIT monoclonal antibody in a mouse colon cancer model enhanced the anti-tumor activity of anti-CTLA-4 and anti-PD-1 therapy by selectively reducing the MDSCs population (144). The gene discussed is CTLA4; the disease is neoplasm.